Figure 6.

Characterization of the TSLPR by affinity cross-linking. (A) 70Z/3 cells were incubated with ¹²⁵I-TSLP in the absence of unlabeled competitor (a and b), or in the presence of unlabeled murine IL-7 (c) or human IL-7 (d) and then treated with (b–d) or without (a) cross-linker. (B) CV-1 cells transfected with TSLPR clone 7a were incubated with ¹²⁵I-TSLP in the absence of unlabeled competitor (e and f) or in the presence of unlabeled TSLP (g) and then treated with (f and g) or without (e) cross-linker. (C) BAF/BO3 cells transfected with muIL-7Rα were incubated with ¹²⁵I-TSLP in the absence of unlabeled competitor (h and i) or in the presence of unlabeled TSLP (j), or with ¹²⁵I–IL-7 (k) and then treated with (i–k) or without (h) cross-linker. Cross-linking was performed as described in Materials and Methods and samples were run on SDS-PAGE under reducing conditions using 8–16% gradient gels and analyzed by autoradiography.